Learn More
Description
The Proliferating Cell Nuclear Antigen (PCNA) was initially identified as a nuclear antigen in proliferating cells and was subsequently described as a subunit for DNA polymerase δ. PCNA protein levels peak during the S-phase of the cell cycle, at which time it forms a complex with the p21 inhibitor. PCNA is almost undetectable in other phases of the cycle. Because of its unique expression, PCNA has been extensively used in studies associating the prognosis of tumor progression and neoplastic proliferation. Human PCNA has been reported to be 262 amino acids with an apparent molecular weight of 36kDa. This antibody is routinely tested by flow cytometric analysis, immunohistochemistry and immunofluorescent imaging. Other applications were tested at BD Biosciences Pharmingen during antibody development only or reported in the literature.
Immunohistochemistry, Immunohistochemistry (Frozen), Intracellular Staining
Specifications
Specifications
| Antigen | PCNA |
| Applications | Flow Cytometry |
| Classification | Monoclonal |
| Clone | PC10 |
| Concentration | 0.5mg/mL |
| Conjugate | Unconjugated |
| Formulation | Aqueous buffered solution containing ≤0.09% sodium azide. |
| Host Species | Mouse |
| Immunogen | Not reported |
| Purification Method | Affinity Purified |
| Show More |
For Research Use Only.
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.